Overview: Kala Azar Aldehyde TestIntroduction: The Kala Azar Aldehyde Test detects a marker for Kala Azar (visceral leishmaniasis), a parasitic infection causing fever, weight loss, or enlarged spleen. Aligned with 2023 WHO guidelines, it uses spectrophotometry for high sensitivity, aiding in confirming parasitic infections. This test is critical for guiding antiparasitic therapy, preventing disease progression, and improving outcomes in infectious disease management.
Other Names: Kala Azar Test, Aldehyde Chopra Test.
FDA Status: Laboratory-developed test (LDT), meeting biochemistry standards for diagnostic accuracy.
Historical Milestone: The aldehyde test was developed in the 1920s for leishmaniasis. Spectrophotometry emerged in the 1970s, and by the 2000s, improved assays enhanced diagnostic specificity.
Purpose: Diagnoses Kala Azar, guides therapy, and monitors disease in patients with fever or spleen enlargement.
Test Parameters: 1. Aldehyde Chopra Test
Pretest Condition: No fasting required. Collect serum at symptom onset. Report fever, weight loss, or travel to endemic areas.
Specimen: 2-5 mL serum (SST). Centrifuge within 1 hour. Transport in a biohazard bag within 8 hours.
Sample Stability at Room Temperature: 8 hours
Sample Stability at Refrigeration: 7 days
Sample Stability at Frozen: 6 months
Medical History: Document fever, weight loss, spleen enlargement, or travel history to endemic areas. Include current medications or infections.
Consent: Written consent required, explaining the test's purpose, diagnostic implications, and potential therapy needs.
Procedural Considerations: Uses spectrophotometry to detect aldehyde reaction products. Results are available in 1-2 days, supporting rapid diagnosis.
Factors Affecting Result Accuracy: Non-leishmanial infections may cause false positives. Hemolysis or improper storage can degrade samples.
Clinical Significance: Positive results suggest Kala Azar, prompting antiparasitic therapy. Negative results may require PCR or bone marrow biopsy.
Specialist Consultation: Consult an infectious disease specialist for result interpretation. Tropical medicine referral is advised for complex cases.
Additional Supporting Tests: Leishmania PCR, bone marrow biopsy, or rK39 antibody test to confirm Kala Azar.
Test Limitations: Non-specific reactions require clinical correlation. False negatives may occur in early infection.
References: WHO Leishmaniasis Guidelines, 2023; Sundar S, Lancet Infectious Diseases, 2022.
